0.4250 -0.01 (-1.76%)
After hours: 5:58PM EDT
|Bid||0.4250 x 1100|
|Ask||0.4390 x 800|
|Day's Range||0.4060 - 0.4500|
|52 Week Range||0.3600 - 1.4800|
|Beta (3Y Monthly)||0.81|
|PE Ratio (TTM)||5.85|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2019 second quarter financial results before the opening of the market on Thursday, July 18, 2019. The Company will host a conference call at 8:00 a.m., Eastern Time on July 18, 2019 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 7357689.
NeuroMetrix, Inc. (NURO), a health technology company addressing chronic health conditions including chronic pain, sleep disorders and diabetes, today reported on its strategy of optimizing its commercial products while reducing operating costs and preserving cash. The Company is focused on supporting its DPNCheck® product line, managing its existing Quell® business while evaluating alternative therapeutic applications for the core technology, maintaining its strategic collaboration with GlaxoSmithKline, and attempting to negotiate a settlement of the previously disclosed and ongoing Federal Trade Commission (FTC) investigation which is centered on Quell advertising. In its efforts to preserve cash, the Company has implemented a reduction in force affecting 11 employees, all of whom have ceased employment with the Company.
NeuroMetrix, Inc. (NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,293,159 titled “Measuring the ‘on-skin’ time of a Transcutaneous Electrical Nerve Stimulator (TENS) device in order to minimize skin irritation due to excessive uninterrupted wearing of the same.” The patent covers novel methods to help Quell® users safely obtain wearable TENS therapy over extended time periods. "We are pleased to have received this latest patent for Quell technology," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. Quell is drug-free and has been cleared by the FDA for relief and management of chronic pain without a prescription.
WALTHAM, Mass., April 25, 2019 -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended March 31, 2019. The Company develops.
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / NeuroMetrix, Inc. (NASDAQ: NURO ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 25, 2019 at 8:00 AM Eastern ...
NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2019 first quarter financial results before the opening of the market on Thursday, April 25, 2019. The Company will host a conference call at 8:00 a.m., Eastern Time on April 25, 2019 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 3589503.
WALTHAM, Mass., Jan. 29, 2019 -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported publication of three new DPNCheck® clinical studies. DPNCheck is a point-of-care test that.
WALTHAM, Mass., Jan. 24, 2019 -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter and year ended December 31, 2018. The.
A total of 68 adult patients with a primary complaint of chronic low back pain were enrolled and randomized with equal probability to treatment with the Quell device (experimental group) or "treatment-as usual" (control group). Study subjects averaged 46.2 ± 12.7 years of age and 60% were female. All subjects reported chronic low back pain as their primary complaint. Over half of the subjects (57%) reported multi-site pain. All subjects used a smartphone app developed by the Pain Management Center that helps patients document and manage their pain. Outcome measures included the Brief Pain Inventory, the Pain Catastrophizing Scale, the Pain Disability Index and the Hospital Anxiety and Depression Scale. All subjects were given Quantitative Sensory Testing at baseline.
Quell® 2.0 was named a CES® 2019 Innovation Awards Honoree in the Fitness, Sports and Biotech product category, recognizing the company’s innovative application of AI + neurotechnology to manage chronic pain. NeuroMetrix President and CEO, Shai Gozani was a speaker at the Digital Health Summit at CES, focusing on the continued advances in healthcare.
WALTHAM, Mass., Jan. 15, 2019 -- NeuroMetrix, Inc. (NASDAQ: NURO) will issue its fourth quarter 2018 financial results on Thursday morning January 24, 2019. A conference call.
NeuroMetrix, Inc. (NURO) announced that it has been named a CES® 2019 Innovation Awards Honoree for Quell® 2.0 Wearable Pain Relief Technology™ in the Fitness, Sports and Biotech product category. The announcement was made during CES 2019, which runs January 8-11, 2019 in Las Vegas, NV. The CES Innovation Awards is an annual competition honoring outstanding design and engineering in consumer technology products. The Quell app has been totally redesigned to make it easier to use. Quell 2.0 will be the first wearable technology to utilize machine learning to deliver unprecedented personalization for the treatment of chronic pain. Additionally, the Quell app will include Therapy Coach to help users achieve the best possible outcomes and a new Intensive Therapy option.
NeuroMetrix Inc. (NURO) today unveiled its smartest, smallest and most powerful wearable therapeutic to date. With new features seen for the first time at CES, the recently launched Quell® 2.0 is 50% smaller, yet 20% more powerful than its predecessor. The Company will introduce new functionality at CES that includes updates to the Quell app like coaching that helps users achieve the best possible outcomes. It also takes Pain Tech to a new level with an Intensive Therapy option and is the first wearable technology to utilize machine learning to deliver unprecedented personalization for the treatment of chronic pain.
NeuroMetrix, Inc. (NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2019 Conference at the Hilton San Francisco Union Square on Monday, January 7, 2019 at 11:30 a.m. (Pacific). Dr. Gozani will highlight the Company's Quell® Wearable Pain Relief Technology™ and provide an update on the Company’s business activities. Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and the life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / NeuroMetrix and Moleculin were both up almost 19% in Tuesday’s trading session. Traders were gearing up for Moleculin’s conference call today discussing a recent discovery of a use of one of its molecules for cancer treatment while NeuroMetrix announced an update on its strategic collaboration with GSK Consumer Healthcare. NeuroMetrix, Inc. shares were up nearly 19% on almost 1.7 million shares traded on Tuesday.
Under terms of the collaboration entered into in the first quarter of 2018, the parties committed to co-fund future development of Quell® technology beginning in 2019, subject to agreement on an annual program of product initiatives. The Company reported that agreement has been reached on the 2019 development program and it will commence in January 2019.
WALTHAM, Mass., Nov. 28, 2018 -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the.
WALTHAM, Mass., Nov. 15, 2018 -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi Co. Ltd. for DPNCheck®, the.
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.